Restricted accessResearch articleFirst published online 2016-08
Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice
Mesenchymal stromal/stem cells (MSCs) constitute progenitor cells that can be isolated from different tissues. Based on their immunomodulatory and neuroprotective functions, MSC-based cell-therapy approaches have been suggested to antagonize inflammatory activity and neuronal damage associated with autoimmune disease of the central nervous system (CNS), for example, multiple sclerosis (MS). Intravenous MSC transplantation was reported to ameliorate experimental autoimmune encephalomyelitis (EAE), the murine model of MS, within days after transplantation. However, systemic distribution patterns and fate of MSCs after administration, especially their potential to migrate into inflammatory lesions within the CNS, remain to be elucidated. This question has of recent become particularly important, since therapeutic infusion of MSCs is now being tested in clinical trials with MS-affected patients. Here, we made use of the established EAE mouse model to investigate migration and therapeutic efficacy of murine bone marrow-derived MSCs. Applying a variety of techniques, including magnetic resonance imaging, immunohistochemistry, fluorescence in-situ hybridization, and quantitative polymerase chain reaction we found no evidence for immediate migration of infused MSC into the CNS of treated mice. Moreover, in contrast to other studies, transplanted MSCs did not ameliorate EAE. In conclusion, our data does not provide substantiation for a relevant migration of infused MSCs into the CNS of EAE mice supporting the hypothesis that potential therapeutic efficacy could be based on systemic effects. Evaluation of possible mechanisms underlying the observed discrepancies in MSC treatment outcomes between different EAE models demands further studies.
Get full access to this article
View all access options for this article.
References
1.
SospedraM and MartinR. (2005). Immunology of multiple sclerosis. Annu Rev Immunol, 23:683–747.
2.
AbramowskiP, SteinbachK, ZanderAR and MartinR. (2014). Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis. J Neuroimmunol, 274:111–124.
3.
ZamvilSS and SteinmanL. (1990). The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol, 8:579–621.
4.
OksenbergJR and HauserSL. (2005). Genetics of multiple sclerosis. Neurol Clin, 23:61–75, vi.
5.
HaflerDA, CompstonA, SawcerS, LanderES, DalyMJ, De JagerPL, de BakkerPIW, GabrielSB, MirelDB, et al. (2007). Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med, 357:851–862.
6.
LundmarkF, DuvefeltK, IacobaeusE, KockumI, WallströmE, KhademiM, OturaiA, RyderLP, SaarelaJ, et al. (2007). Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet, 39:1108–1113.
7.
McElroyJP and OksenbergJR. (2008). Multiple sclerosis genetics. Curr Top Microbiol Immunol, 318:45–72.
8.
SawcerS, HellenthalG, PirinenM, SpencerCCA, PatsopoulosNA, MoutsianasL, DiltheyA, SuZ, FreemanC, et al. (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 476:214–219.
9.
LünemannJD, EdwardsN, MuraroPA, HayashiS, CohenJI, MünzC and MartinR. (2006). Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain, 129:1493–1506.
10.
LünemannJD, JelcićI, RobertsS, LutterottiA, TackenbergB, MartinR and MünzC. (2008). EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med, 205:1763–1773.
11.
ThackerEL, MirzaeiF and AscherioA. (2006). Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol, 59:499–503.
12.
LemireJM and ArcherDC. (1991). 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest, 87:1103–1107.
13.
MungerKL, LevinLI, HollisBW, HowardNS and AscherioA. (2006). Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 296:2832–2838.
14.
MungerKL, ZhangSM, O'ReillyE, HernánMA, OlekMJ, WillettWC and AscherioA. (2004). Vitamin D intake and incidence of multiple sclerosis. Neurology, 62:60–65.
15.
RiiseT, NortvedtMW and AscherioA. (2003). Smoking is a risk factor for multiple sclerosis. Neurology, 61:1122–1124.
16.
FujinamiRS, von HerrathMG, ChristenU and WhittonJL. (2006). Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev, 19:80–94.
17.
ConfavreuxC, AimardG and DevicM. (1980). Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain, 103:281–300.
18.
RunmarkerB and AndersenO. (1993). Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain, 116 (Pt 1):117–134.
19.
NoseworthyJH, LucchinettiC, RodriguezM and WeinshenkerBG. (2000). Multiple sclerosis. N Engl J Med, 343:938–952.
20.
LassmannH, BrückW and LucchinettiCF. (2007). The immunopathology of multiple sclerosis: an overview. Brain Pathol, 17:210–218.
21.
ConfavreuxC, VukusicS, MoreauT and AdeleineP. (2000). Relapses and progression of disability in multiple sclerosis. N Engl J Med, 343:1430–1438.
22.
PatrikiosP, StadelmannC, KutzelniggA, RauschkaH, SchmidbauerM, LaursenH, SorensenPS, BrückW, LucchinettiC and LassmannH. (2006). Remyelination is extensive in a subset of multiple sclerosis patients. Brain, 129:3165–3172.
23.
PrineasJW, BarnardRO, KwonEE, SharerLR and ChoES. (1993). Multiple sclerosis: remyelination of nascent lesions. Ann Neurol, 33:137–151.
24.
BurtRK, TraynorAE, PopeR, SchroederJ, CohenB, KarlinKH, LobeckL, GoolsbyC, RowlingsP, et al. (1998). Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood, 92:3505–3514.
25.
GuillaumeT, RubinsteinDB and SymannM. (1998). Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood, 92:1471–1490.
26.
MancardiG, SormaniM, GualandiF, SaizA, CarrerasE, MerelliE, DonelliA, LugaresiA, Di BartolomeoP, et al. (2015). Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. Neurology, 84:981–988.
27.
RiceCM, MallamEA, WhoneAL, WalshP, BrooksDJ, KaneN, ButlerSR, MarksDI and ScoldingNJ. (2010). Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther, 87:679–685.
28.
UccelliA, MorettaL and PistoiaV. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol, 8:726–736.
29.
GrohME, MaitraB, SzekelyE and KoçON. (2005). Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol, 33:928–934.
30.
KramperaM, CosmiL, AngeliR, PasiniA, LiottaF, AndreiniA, SantarlasciV, MazzinghiB, PizzoloG, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24:386–398.
31.
RenG, SuJ, ZhangL, ZhaoX, LingW, L'huillieA, ZhangJ, LuY, RobertsAI, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27:1954–1962.
32.
RyanJM, BarryF, MurphyJM and MahonBP. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 149:353–363.
33.
SingerNG and CaplanAI. (2011). Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol, 6:457–478.
34.
DarnellJE, KerrIM and StarkGR. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264:1415–1421.
35.
SatoK, OzakiK, OhI, MeguroA, HatanakaK, NagaiT, MuroiK and OzawaK. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109:228–234.
36.
ChoKJ, TrzaskaKA, GrecoSJ, McArdleJ, WangFS, YeJ-H and RameshwarP. (2005). Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells, 23:383–391.
37.
LanzaC, MorandoS, VociA, CanesiL, PrincipatoMC, SerperoLD, MancardiG, UccelliA and VerganiL. (2009). Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem, 110:1674–1684.
38.
WilkinsA, KempK, GintyM, HaresK, MallamE and ScoldingN. (2009). Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res, 3:63–70.
39.
IldstadST and SachsDH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature, 307:168–170.
40.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS and GianniAM. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
41.
BartholomewA, SturgeonC, SiatskasM, FerrerK, McIntoshK, PatilS, HardyW, DevineS, UckerD, et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol, 30:42–48.
SasakiM, HonmouO, AkiyamaY, UedeT, HashiK and KocsisJD. (2001). Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia, 35:26–34.
44.
ChenJ, SanbergPR, LiY, WangL, LuM, WillingAE, Sanchez-RamosJ and ChoppM. (2001). Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke, 32:2682–2688.
45.
ChoppM, ZhangXH, LiY, WangL, ChenJ, LuD, LuM and RosenblumM. (2000). Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation. Neuroreport, 11:3001–3005.
46.
SchwarzEJ, AlexanderGM, ProckopDJ and AziziSA. (1999). Multipotential marrow stromal cells transduced to produce L-DOPA: engraftment in a rat model of Parkinson disease. Hum Gene Ther, 10:2539–2549.
47.
LeeRH, SeoMJ, RegerRL, SpeesJL, PulinAA, OlsonSD and ProckopDJ. (2006). Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A, 103:17438–17443.
48.
BaiL, LennonDP, EatonV, MaierK, CaplanAI, MillerSD and MillerRH. (2009). Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia, 57:1192–1203.
49.
ZhangJ, LiY, ChenJ, CuiY, LuM, EliasSB, MitchellJB, HammillL, VanguriP and ChoppM. (2005). Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol, 195:16–26.
GerdoniE, GalloB, CasazzaS, MusioS, BonanniI, PedemonteE, MantegazzaR, FrassoniF, MancardiG, PedottiR and UccelliA. (2007). Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol, 61:219–227.
52.
SchäferR, AyturanM, BantleonR, KehlbachR, SiegelG, PintaskeJ, ConradS, WolburgH, NorthoffH, WiskirchenJ and WeissertR. (2008). The use of clinically approved small particles of iron oxide (SPIO) for labeling of mesenchymal stem cells aggravates clinical symptoms in experimental autoimmune encephalomyelitis and influences their in vivo distribution. Cell Transplant, 17:923–941.
53.
MillerSD, KarpusWJ and DavidsonTS. (2010). Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol Chapter 15:Unit15.1.
54.
LangeC, SchroederJ, StuteN, LioznovMV and ZanderAR. (2005). High-potential human mesenchymal stem cells. Stem Cells Dev, 14:70–80.
55.
WeberK and FehseB. (2009). Diva-Fit: a step-by-step manual for generating high-resolution graphs and histogram overlays of flow cytometry data obtained with FACSDiva software. Cell Ther Transplant, 1:1–4.
IttrichH, LangeC, DahnkeH, ZanderAR, AdamG and Nolte-ErnstingC. (2005). Labeling of mesenchymal stem cells with different superparamagnetic particles of iron oxide and detectability with MRI at 3T. RoFo, 177:1151–1163.
58.
PeldschusK, KaulM, LangeC, Nolte-ErnstingC, AdamG and IttrichH. (2007). Magnetic resonance imaging of single SPIO labeled mesenchymal stem cells at 3 Tesla. RoFo, 179:473–479.
59.
SoloveiI. (2010). Fluorescence in situ hybridization (FISH) on tissue cryosections. Methods Mol Biol, 659:71–82.
60.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
61.
IttrichH, LangeC, TögelF, ZanderAR, DahnkeH, WestenfelderC, AdamG and Nolte-ErnstingC. (2007). In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T. J Magn Reson Imaging, 25:1179–1191.
62.
LangeC, TögelF, IttrichH, ClaytonF, Nolte-ErnstingC, ZanderAR and WestenfelderC. (2005). Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int, 68:1613–1617.
63.
FischerUM, HartingMT, JimenezF, Monzon-PosadasWO, XueH, SavitzSI, LaineGA and CoxCS. (2009). Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev, 18:683–692.
64.
GaoJ, DennisJE, MuzicRF, LundbergM and CaplanAI. (2001). The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs, 169:12–20.
65.
KurtzA. (2008). Mesenchymal stem cell delivery routes and fate. Int J Stem Cells, 1:1–7.
66.
LeeRH, PulinAA, SeoMJ, KotaDJ, YlostaloJ, LarsonBL, Semprun-PrietoL, DelafontaineP and ProckopDJ. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5:54–63.
67.
SchrepferS, DeuseT, ReichenspurnerH, FischbeinMP, RobbinsRC and PelletierMP. (2007). Stem cell transplantation: the lung barrier. Transplant Proc, 39:573–576.
68.
AbramowskiP, OttoB and MartinR. (2014). The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response. PLoS One, 9:e91970.
69.
GoldR, KapposL, ArnoldDL, Bar-OrA, GiovannoniG, SelmajK, TornatoreC, SweetserMT, YangM, SheikhSI and DawsonKT. (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med, 367:1098–1107.
70.
O'ConnorP, WolinskyJS, ConfavreuxC, ComiG, KapposL, OlssonTP, BenzerdjebH, TruffinetP, WangL, MillerA and FreedmanMS. (2011). Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med, 365:1293–1303.
71.
LutterottiA, YousefS, SputtekA, StürnerKH, StellmannJ-P, BreidenP, ReinhardtS, SchulzeC, BesterM, et al. (2013). Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med, 5:188ra75.
72.
SchattlingB, SteinbachK, ThiesE, KruseM, MenigozA, UferF, FlockerziV, BrückW, PongsO, et al. (2012). TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med, 18:1805–1811.
73.
EggenhoferE, LukF, DahlkeMH and HoogduijnMJ. (2014). The life and fate of mesenchymal stem cells. Front Immunol, 5:148.
74.
SajicM, HuntDPJ, LeeW, CompstonDAS, SchweimerJV, GregsonNA, ChandranS and SmithKJ. (2012). Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation. PLoS One, 7:e30708.
75.
BererK, MuesM, KoutrolosM, Al RasbiZ, BozikiM, JohnerC, WekerleH and KrishnamoorthyG. (2011). Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature, 479:538–541.
76.
SelichA, DaudertJ, HassR, PhilippF, von KaisenbergC, PaulG, CornilsK, FehseB, RittinghausenS, SchambachA and RotheM. (2016). Massive clonal selection and transiently contributing clones during expansion of mesenchymal stem cell cultures revealed by lentiviral RGB-barcode technology. Stem Cells Transl Med, 5:591–601.
77.
PedemonteE, BenvenutoF, CasazzaS, MancardiG, OksenbergJR, UccelliA and BaranziniSE. (2007). The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics, 8:65.
78.
RafeiM, CampeauPM, Aguilar-MahechaA, BuchananM, WilliamsP, BirmanE, YuanS, YoungYK, BoivinM-N, et al. (2009). Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol, 182:5994–6002.
79.
ZhangJ, LiY, LuM, CuiY, ChenJ, NoffsingerL, EliasSB and ChoppM. (2006). Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res, 84:587–595.
80.
ZhangX, BowlesAC, SemonJA, ScruggsBA, ZhangS, StrongAL, GimbleJM and BunnellBA. (2014). Transplantation of autologous adipose stem cells lacks therapeutic efficacy in the experimental autoimmune encephalomyelitis model. PLoS One, 9:e85007.
81.
GordonD, PavlovskaG, GloverCP, UneyJB, WraithD and ScoldingNJ. (2008). Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett, 448:71–73.
82.
GordonD, PavlovskaG, UneyJB, WraithDC and ScoldingNJ. (2010). Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol, 69:1087–1095.
83.
NesslerJ, BénardaisK, GudiV, HoffmannA, Salinas TejedorL, JanßenS, PrajeethCK, BaumgärtnerW, KavelaarsA, et al. (2013). Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination. PLoS One, 8:e69795.
84.
Salinas TejedorL, BernerG, JacobsenK, GudiV, JungwirthN, HansmannF, GingeleS, PrajeethCK, BaumgärtnerW, et al. (2015). Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system. Brain Behav Immun, 50:155–165.
85.
ChiesaS, MorbelliS, MorandoS, MassolloM, MariniC, BertoniA, FrassoniF, BartolomeST, SambucetiG, TraggiaiE and UccelliA. (2011). Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci, 108:17384–17389.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
